Treatment with an AAV to upregulate Pcsk9 in the liver is a recently developed atherogenic model that can induce hyperlipidemia and lesion formation in mice fed an AD without the requirement of crossbreeding into an atheroprone background [18, 19]. The gene discussed is PCSK9; the disease is hyperlipidemia.